Status:
COMPLETED
Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-Infected Patients
Lead Sponsor:
University Hospital, Bordeaux
Collaborating Sponsors:
Hoffmann-La Roche
Ministry of Health, France
Conditions:
HIV Infections
Hepatitis C, Chronic
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Combination of PEG interferon and ribavirin is the standard treatment of chronic hepatitis C. Efficacy of this treatment has never been evaluated in HCV-HIV infected patients, who have previously been...
Eligibility Criteria
Inclusion
- Chronic hepatitis C : Detectable HCV RNA, Previously treated with interferon or interferon combined with ribavirin, Elevated ALT level
- HIV infection (CD4\>250/µL, HIV RNA\<10 000 copies/ml) treated or not with antiretroviral therapy
- Signed informed consent
Exclusion
- Chronic hepatitis B
- Alcohol consumption\>40g/day
- Evidence of decompensated liver disease
- Hepatocellular carcinoma
- Other relevant disorders: organ transplantation, psychiatric or cardiovascular disease, poorly controlled diabetes, seizure disorders, hemoglobinopathy, autoimmune disease
Key Trial Info
Start Date :
April 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2004
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT00221650
Start Date
April 1 2002
End Date
June 1 2004
Last Update
June 13 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Pellegrin, Federation des Maladies Infectieuses, Pr RAGNAUD
Bordeaux, France, 33076